Remove Hospital Remove Safety Remove Therapy
article thumbnail

Godfrey Town has been appointed Senior Research Fellow

Online Laser Training

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

article thumbnail

Godfrey Town has been appointed Senior Research Fellow

Online Laser Training

Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark where he plans to assist Clinical Professor of Dermatology Peter Bjerring MD, Dr.Sci., Department of Clinical Medicine at Aalborg University Hospital to build a new dermatological research area with collaboration with other specialities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

INmune Bio to Submit FDA BLA for CORDStrom in RDEB

The Dermatology Digest

The submission will be supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients. About MissionEB The MissionEB study, led by Dr. Anna Martinez and team at the Great Ormond Street Hospital (GOSH) London, U.K.,

article thumbnail

Dupilumab (Dupixent, Sanofi & Regeneron) Shows More Promise in BP

The Dermatology Digest

The safety and efficacy of dupilumab in BP are currently under clinical investigation and have not been evaluated by any regulatory authority. Sustained disease remission was defined as complete clinical remission with completion of OCS taper by week 16 without relapse and no rescue therapy use during the 36-week treatment period.

article thumbnail

Meet the First-ever Recipients of The Lupus Research Alliance’s Translational Bridge Award

The Dermatology Digest

This could help doctors better predict which therapies will work best for each patient. He will test ONT01, which has shown promising results in mouse models, in a phase 1b trial to assess its safety in people with lupus. This trial could open the door to a new class of treatments that target lupus at the molecular level.

article thumbnail

EMA’s CHMP Recommends Krystal’s Vyjuvek for Dystrophic Epidermolysis Bullosa

The Dermatology Digest

We are very pleased that our patients, from birth, will have a simple, topical treatment that promotes durable wound closure, something that until now has been beyond the reach of any therapy, adds Christine Bodemer, MD, PhD, Professor and Head of the Department of Dermatology at the Necker Enfants Malades Hospital in Paris.

Therapy 36
article thumbnail

Arch Amenities’ Catherine Warren on technology & creating memorable experiences.

Spa Executive

We asked her about what she does, technology’s role in the hospitality and wellness space, and creating memorable experiences. Travel itself is inherently taxing on the mind and body, making it essential for hospitality providers to address these aspects to ensure a truly restorative experience.